Skip to main content
NASDAQ:BMRN

BioMarin Pharmaceutical News Headlines

$76.93
+1.42 (+1.88 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$75.59
$77.52
50-Day Range
$74.76
$81.16
52-Week Range
$71.35
$131.95
Volume933,064 shs
Average Volume1.19 million shs
Market Capitalization$14.06 billion
P/E Ratio17.60
Dividend YieldN/A
Beta0.71

Headlines

BioMarin Pharmaceutical (NASDAQ BMRN) News Headlines Today

SourceHeadline
BioMarin Pharmaceutical (NASDAQ:BMRN) Research Coverage Started at Credit Suisse GroupBioMarin Pharmaceutical (NASDAQ:BMRN) Research Coverage Started at Credit Suisse Group
marketbeat.com - April 29 at 9:41 AM
Is the Rally Ready to Begin for BioMarin Pharmaceutical? Is the Rally Ready to Begin for BioMarin Pharmaceutical?
marketbeat.com - April 28 at 6:28 PM
Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $657,970 of SharesBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $657,970 of Shares
uk.finance.yahoo.com - May 13 at 2:49 AM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $657,969.77 in StockBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $657,969.77 in Stock
americanbankingnews.com - May 12 at 8:50 PM
Biomarin Pharmaceutical Inc (BMRN) EVP, CFO Brian Mueller Sold $533,366 of SharesBiomarin Pharmaceutical Inc (BMRN) EVP, CFO Brian Mueller Sold $533,366 of Shares
uk.finance.yahoo.com - May 12 at 6:47 AM
$0.27 Earnings Per Share Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter$0.27 Earnings Per Share Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter
americanbankingnews.com - May 11 at 11:26 PM
Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CFO Sells 6,709 Shares of StockInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CFO Sells 6,709 Shares of Stock
americanbankingnews.com - May 11 at 8:46 PM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $1,953,000.00 in StockBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Sells $1,953,000.00 in Stock
americanbankingnews.com - May 10 at 11:36 PM
BioMarin Pharmaceutical (NASDAQ:BMRN) Updates FY 2021 Earnings GuidanceBioMarin Pharmaceutical (NASDAQ:BMRN) Updates FY 2021 Earnings Guidance
americanbankingnews.com - May 6 at 1:30 PM
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Buy" by BrokeragesBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - May 5 at 10:44 AM
Was The Smart Money Right About BioMarin (BMRN)?Was The Smart Money Right About BioMarin (BMRN)?
finance.yahoo.com - May 4 at 5:51 PM
Estimating The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Estimating The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
ca.finance.yahoo.com - May 3 at 4:48 PM
BioMarin Reports Better-Than-Expected 1Q ResultsBioMarin Reports Better-Than-Expected 1Q Results
finance.yahoo.com - April 30 at 1:23 PM
BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide DecisionBioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision
finance.yahoo.com - April 30 at 1:23 PM
Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call TranscriptBiomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript
finance.yahoo.com - April 30 at 7:52 AM
BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2021 Earnings GuidanceBioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2021 Earnings Guidance
americanbankingnews.com - April 29 at 6:24 PM
Biomarin Pharmaceutical Inc. Reports Retreat In Q1 ProfitBiomarin Pharmaceutical Inc. Reports Retreat In Q1 Profit
nasdaq.com - April 29 at 6:21 PM
BioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated by Analysts at Credit Suisse GroupBioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated by Analysts at Credit Suisse Group
americanbankingnews.com - April 29 at 9:32 AM
Preview: Biomarin Pharmaceuticals EarningsPreview: Biomarin Pharmaceutical's Earnings
benzinga.com - April 28 at 2:58 PM
Wedbush Reaffirms Buy Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)Wedbush Reaffirms Buy Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)
americanbankingnews.com - April 28 at 12:20 PM
Allen Institute, BioMarin To Develop Gene Therapies For Rare Brain DiseasesAllen Institute, BioMarin To Develop Gene Therapies For Rare Brain Diseases
markets.businessinsider.com - April 28 at 9:40 AM
Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain DiseasesAllen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases
finance.yahoo.com - April 28 at 9:40 AM
Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $1.6 million of SharesBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $1.6 million of Shares
uk.finance.yahoo.com - April 27 at 12:10 AM
Morgan Stanley Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $82.00Morgan Stanley Cuts BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $82.00
americanbankingnews.com - April 26 at 9:58 AM
$445.44 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter$445.44 Million in Sales Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter
americanbankingnews.com - April 26 at 3:28 AM
$0.32 EPS Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter$0.32 EPS Expected for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Quarter
americanbankingnews.com - April 24 at 8:08 AM
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - April 22 at 2:55 PM
First Trust Lunt U.S. Factor Rotation ETF Experiences Big OutflowFirst Trust Lunt U.S. Factor Rotation ETF Experiences Big Outflow
nasdaq.com - April 16 at 3:10 PM
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment ChoiceBioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice
finance.yahoo.com - April 15 at 1:14 PM
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ETBioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
finance.yahoo.com - April 13 at 4:08 PM
Noteworthy Wednesday Option Activity: BMRN, PLCE, KEXNoteworthy Wednesday Option Activity: BMRN, PLCE, KEX
nasdaq.com - April 7 at 4:45 PM
Biomarin Pharmaceutical Stock Is Estimated To Be Modestly UndervaluedBiomarin Pharmaceutical Stock Is Estimated To Be Modestly Undervalued
finance.yahoo.com - March 28 at 10:57 PM
BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 27 at 4:53 PM
Is BioMarin (BMRN) Stock A Buy or Sell?Is BioMarin (BMRN) Stock A Buy or Sell?
finance.yahoo.com - March 21 at 10:44 PM
BioMarin Announces Oral Presentation at ENDO2021...BioMarin Announces Oral Presentation at ENDO2021...
benzinga.com - March 20 at 2:46 PM
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Societys Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with VosoritideBioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
finance.yahoo.com - March 20 at 2:46 PM
BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc ...BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc ...
businesswire.com - March 20 at 9:46 AM
BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRNBIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
finance.yahoo.com - March 19 at 11:21 PM
Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $1.1 million of SharesBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $1.1 million of Shares
finance.yahoo.com - March 16 at 2:31 AM
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDAs RMAT TagBioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
finance.yahoo.com - March 9 at 2:35 PM
BioMarins Hemophilia Gene Therapy Scores RMAT Designation In USBioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US
finance.yahoo.com - March 8 at 6:31 PM
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia ABioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
finance.yahoo.com - March 8 at 1:30 PM
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with AchondroplasiaBioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
finance.yahoo.com - March 3 at 10:14 AM
BioMarin Pharmaceuticals (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call TranscriptBioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 27 at 2:47 PM
BIOMARIN INVESTIGATION INITIATED BY FORMER...BIOMARIN INVESTIGATION INITIATED BY FORMER...
benzinga.com - February 27 at 9:46 AM
BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL:  Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRNBIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN
markets.businessinsider.com - February 26 at 11:27 PM
Noteworthy Friday Option Activity: BMRN, ZNGA, ZYXINoteworthy Friday Option Activity: BMRN, ZNGA, ZYXI
nasdaq.com - February 26 at 7:15 PM
Why Biomarin Pharmaceuticals Stock is Down During Todays SessionWhy Biomarin Pharmaceutical's Stock is Down During Today's Session
msn.com - February 26 at 1:24 PM
BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View DullBioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull
finance.yahoo.com - February 26 at 1:24 PM
Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call TranscriptBiomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 26 at 1:24 PM
Biomarin Pharmaceutical Inc. Bottom Line Rises In Q4Biomarin Pharmaceutical Inc. Bottom Line Rises In Q4
nasdaq.com - February 25 at 8:12 PM
Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $585,060 of SharesBiomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $585,060 of Shares
ca.finance.yahoo.com - February 24 at 1:09 PM
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.